Cargando…

Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan

BACKGROUNDS: Limited information is available on the utility values of metastatic pancreatic cancer, focusing on different health statuses, selected chemotherapy, and related grades 1/2 and 3/4 adverse events (AEs). We evaluated Japanese societal-based health-related utility values for metastatic pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuki, Takumoto, Yuriko, Sasahara, Hirohito, Narimatsu, Tatsunori, Murata, Manabu, Akazawa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789314/
https://www.ncbi.nlm.nih.gov/pubmed/36564539
http://dx.doi.org/10.1186/s13561-022-00413-8
_version_ 1784858925143687168
author Yuki, Takumoto
Yuriko, Sasahara
Hirohito, Narimatsu
Tatsunori, Murata
Manabu, Akazawa
author_facet Yuki, Takumoto
Yuriko, Sasahara
Hirohito, Narimatsu
Tatsunori, Murata
Manabu, Akazawa
author_sort Yuki, Takumoto
collection PubMed
description BACKGROUNDS: Limited information is available on the utility values of metastatic pancreatic cancer, focusing on different health statuses, selected chemotherapy, and related grades 1/2 and 3/4 adverse events (AEs). We evaluated Japanese societal-based health-related utility values for metastatic pancreatic cancer by considering different grade toxicities commonly associated with chemotherapy using the vignette-based method. METHODS: We developed health status scenarios for patients with metastatic pancreatic cancer undergoing chemotherapy and conducted utility research using the developed scenarios in four steps: ‘literature review,’ ‘exploratory interview,’ ‘content validation’, and ‘utility research’. In the development process, to consider the impact of AEs of chemotherapy for metastatic pancreatic cancer on health state utility values, we selected neutropenia, febrile neutropenia, diarrhea, nausea and vomiting, and neuropathy as representative AEs. Each AE was classified as either grade 1/2 or 3/4. We confirmed our created scenarios through cognitive interviews with the general population and clinical experts to validate the content. Finally, we developed 11 scenarios for using ‘utility research,’ evaluated in a societal-based valuation study using the face-to-face method. Participants for ‘utility research’ were the general population, and they evaluated these scenarios in the composite time trade-off (cTTO) and visual analog scale (VAS) of the European quality of life (EuroQol) valuation technology to derive health state utility scores. RESULTS: Of 220 responders who completed this survey, 201 were adapted into the analysis population. Stable disease with no AEs (reference state) had a mean utility value of 0.653 using cTTO. The lowest mean utility score in the stable state was 0.242 (stable disease + grade 3/4 vomiting). VAS results ranged from 0.189 to 0.468, depending on the various grades of AEs in stable disease. In addition, grade 3/4 AEs and grade 1/2 nausea/vomiting were associated with significantly greater disutility. Utility values were also strongly influenced by the direct impact of AE on physical symptoms, severity and their experience. In addition, 95.9% of the respondents agreed that they understood the questions in the post-response questionnaire. CONCLUSIONS: We clarified the health state utility values of patients with metastatic pancreatic cancer based on the general population in Japan. The effect on utilities should be considered not only for serious AEs, but also for minor AEs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13561-022-00413-8.
format Online
Article
Text
id pubmed-9789314
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-97893142022-12-25 Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan Yuki, Takumoto Yuriko, Sasahara Hirohito, Narimatsu Tatsunori, Murata Manabu, Akazawa Health Econ Rev Research BACKGROUNDS: Limited information is available on the utility values of metastatic pancreatic cancer, focusing on different health statuses, selected chemotherapy, and related grades 1/2 and 3/4 adverse events (AEs). We evaluated Japanese societal-based health-related utility values for metastatic pancreatic cancer by considering different grade toxicities commonly associated with chemotherapy using the vignette-based method. METHODS: We developed health status scenarios for patients with metastatic pancreatic cancer undergoing chemotherapy and conducted utility research using the developed scenarios in four steps: ‘literature review,’ ‘exploratory interview,’ ‘content validation’, and ‘utility research’. In the development process, to consider the impact of AEs of chemotherapy for metastatic pancreatic cancer on health state utility values, we selected neutropenia, febrile neutropenia, diarrhea, nausea and vomiting, and neuropathy as representative AEs. Each AE was classified as either grade 1/2 or 3/4. We confirmed our created scenarios through cognitive interviews with the general population and clinical experts to validate the content. Finally, we developed 11 scenarios for using ‘utility research,’ evaluated in a societal-based valuation study using the face-to-face method. Participants for ‘utility research’ were the general population, and they evaluated these scenarios in the composite time trade-off (cTTO) and visual analog scale (VAS) of the European quality of life (EuroQol) valuation technology to derive health state utility scores. RESULTS: Of 220 responders who completed this survey, 201 were adapted into the analysis population. Stable disease with no AEs (reference state) had a mean utility value of 0.653 using cTTO. The lowest mean utility score in the stable state was 0.242 (stable disease + grade 3/4 vomiting). VAS results ranged from 0.189 to 0.468, depending on the various grades of AEs in stable disease. In addition, grade 3/4 AEs and grade 1/2 nausea/vomiting were associated with significantly greater disutility. Utility values were also strongly influenced by the direct impact of AE on physical symptoms, severity and their experience. In addition, 95.9% of the respondents agreed that they understood the questions in the post-response questionnaire. CONCLUSIONS: We clarified the health state utility values of patients with metastatic pancreatic cancer based on the general population in Japan. The effect on utilities should be considered not only for serious AEs, but also for minor AEs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13561-022-00413-8. Springer Berlin Heidelberg 2022-12-24 /pmc/articles/PMC9789314/ /pubmed/36564539 http://dx.doi.org/10.1186/s13561-022-00413-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yuki, Takumoto
Yuriko, Sasahara
Hirohito, Narimatsu
Tatsunori, Murata
Manabu, Akazawa
Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan
title Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan
title_full Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan
title_fullStr Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan
title_full_unstemmed Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan
title_short Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan
title_sort health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in japan
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789314/
https://www.ncbi.nlm.nih.gov/pubmed/36564539
http://dx.doi.org/10.1186/s13561-022-00413-8
work_keys_str_mv AT yukitakumoto healthstateutilityvaluesformetastaticpancreaticcancerusingacompositetimetradeoffbasedonthevignettebasedapproachinjapan
AT yurikosasahara healthstateutilityvaluesformetastaticpancreaticcancerusingacompositetimetradeoffbasedonthevignettebasedapproachinjapan
AT hirohitonarimatsu healthstateutilityvaluesformetastaticpancreaticcancerusingacompositetimetradeoffbasedonthevignettebasedapproachinjapan
AT tatsunorimurata healthstateutilityvaluesformetastaticpancreaticcancerusingacompositetimetradeoffbasedonthevignettebasedapproachinjapan
AT manabuakazawa healthstateutilityvaluesformetastaticpancreaticcancerusingacompositetimetradeoffbasedonthevignettebasedapproachinjapan